id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-328856-1l7x72j7	Ucciferri, Claudio	Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients	2020-07-01		.txt	text/plain	1207	83	45	Several studies on COVID-19 are focusing on severe forms; however, the most frequent SARS-CoV-2 clinical presentation is a mild disease with or without pneumonia in about 80% of patients. Notwithstanding immune response appeared fundamental for SARS infection resolution, SARS-Cov-2 disease present increased levels of plasma pro-inflammatory mediators, as a consequence of an induced dysregulated cytokine storm. We enrolled SARS-CoV2 positive patients (Brescia-COVID Respiratory Severity Scale 0), with fever and cough without acute respiratory failure or sign of pneumonia from March to April 2020 at the Infectious Diseases Clinic, University 'G. 9 In our study, in the outpatient population affected by SARS-CoV2 infection, pidotimod appears as a valid option to reduce the duration of symptoms in patients, as an earlier defervescence of fever and it could prevent the cytokine cascade activation. In conclusion, in ambulatorial adult patients with SARS-Cov2 infection without pneumonia, pidotimod could be considered an option, well tolerated and associated with a rapid reduction of systemic symptoms of disease.	./cache/cord-328856-1l7x72j7.txt	./txt/cord-328856-1l7x72j7.txt